Discontinued — last reported Q4 '25
Operating Lease Liabilities (Current)
Regeneron Pharmaceuticals Operating Lease Liabilities (Current) increased by 24.8% to $37.80M in Q4 2025 compared to the prior quarter. Over 3 years (FY 2022 to FY 2025), Operating Lease Liabilities (Current) shows an upward trend with a 45.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests an expanding physical footprint or upcoming renewals, while a decrease may indicate store closures or a shift toward asset ownership.
Detailed definition
The portion of operating lease payments due within the next twelve months, representing the short-term obligation for re...
Peer comparison
Retail-heavy tech companies often show higher current lease liabilities compared to pure software firms due to physical storefront presence.
operating_lease_liabilities_currentHistorical Data
| Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|
| Value | $12.40M | $19.00M | $30.30M | $37.80M |
| QoQ Change | — | +53.2% | +59.5% | +24.8% |
| YoY Change | — | +53.2% | +59.5% | +24.8% |
Operating Lease Liabilities (Current) at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's operating lease liabilities (current)?
- Regeneron Pharmaceuticals (REGN) reported operating lease liabilities (current) of $37.80M in Q4 2025.
- What is the long-term trend for Regeneron Pharmaceuticals's operating lease liabilities (current)?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's operating lease liabilities (current) has grown at a 45.0% compound annual growth rate (CAGR), from $12.40M to $37.80M.
- What does operating lease liabilities (current) mean?
- The amount of rent and lease payments the company must pay in the next year.